KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Halozyme Therapeutics (HALO) over the last 13 years, with Q3 2025 value amounting to $282.3 million.

  • Halozyme Therapeutics' Short-term Investments fell 4486.24% to $282.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.3 million, marking a year-over-year decrease of 4486.24%. This contributed to the annual value of $480.2 million for FY2024, which is 12066.08% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Short-term Investments is $282.3 million, which was down 4486.24% from $486.3 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Short-term Investments ranged from a high of $668.3 million in Q1 2022 and a low of $118.4 million during Q3 2022
  • For the 5-year period, Halozyme Therapeutics' Short-term Investments averaged around $329.4 million, with its median value being $298.8 million (2024).
  • In the last 5 years, Halozyme Therapeutics' Short-term Investments skyrocketed by 18242.16% in 2021 and then plummeted by 7933.17% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Short-term Investments (Quarter) stood at $622.2 million in 2021, then crashed by 79.33% to $128.6 million in 2022, then soared by 69.23% to $217.6 million in 2023, then soared by 120.66% to $480.2 million in 2024, then crashed by 41.22% to $282.3 million in 2025.
  • Its Short-term Investments stands at $282.3 million for Q3 2025, versus $486.3 million for Q2 2025 and $571.6 million for Q1 2025.